Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Conference Presentations
, 2014, 'Abstract 5138: Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1', http://dx.doi.org/10.1158/1538-7445.am2014-5138
, 2014, 'Abstract 997: Targeting the Jak/Stat signaling pathway is highly effective in xenograft models of early T cell precursor (ETP) acute lymphoblastic leukemia (ALL)', http://dx.doi.org/10.1158/1538-7445.am2014-997
Conference Abstracts
, 2026, 'Abstract 4030: Targeting MYB with REM-422 for the treatment of pediatric T-cell acute lymphoblastic leukemia - A report from the Pediatric Preclinical Testing Consortium (PIVOT)', in Cancer Research, American Association for Cancer Research (AACR), Vol. 86, pp. 4030 - 4030, http://dx.doi.org/10.1158/1538-7445.am2026-4030
, 2025, 'Abstract A002-PR011: Precision Diagnosis in High-Risk Pediatric Oncology through Integrated Whole Genome, Transcriptome, and Epigenome Profiling', in Cancer Research, American Association for Cancer Research (AACR), Vol. 85, pp. a002-pr011-a002-pr011, http://dx.doi.org/10.1158/1538-7445.pediatric25-a002-pr011
, 2025, 'Abstract IA017: Single mouse testing (SMT): An alternative approach to encompass clinical heterogeneity of pediatric cancers', in Cancer Research, American Association for Cancer Research (AACR), Vol. 85, pp. ia017 - ia017, http://dx.doi.org/10.1158/1538-7445.genfunc25-ia017
, 2024, 'DIPG-48. PRECISION GUIDED THERAPY PROVIDES CLINICAL BENEFIT IN H3K27-ALTERED DIFFUSE MIDLINE GLIOMA', in Neuro-Oncology, Oxford University Press (OUP), Vol. 26, http://dx.doi.org/10.1093/neuonc/noae064.101
, 2024, 'DIPG-48. PRECISION GUIDED THERAPY PROVIDES CLINICAL BENEFIT IN H3K27-ALTERED DIFFUSE MIDLINE GLIOMA', in Neuro-oncology, Vol. 26
, 2023, 'Abstract B134: Targeting Philadelphia chromosome-like acute lymphoblastic leukemia with a novel CRLF2 antibody fragment-drug conjugate', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 22, pp. b134 - b134, http://dx.doi.org/10.1158/1535-7163.targ-23-b134
, 2023, 'Abstract C095: The menin inhibitor VTP-50469 enhances the in vivo efficacy of established drugs against preclinical models of aggressive infant MLL-r acute lymphoblastic leukemia', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 22, pp. c095 - c095, http://dx.doi.org/10.1158/1535-7163.targ-23-c095
, 2023, 'The AKR1C3-Activated Prodrug, Achm-025, Eradicates Disease in Preclinical Models of Aggressive T-Cell Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, Vol. 142, pp. 4251, http://dx.doi.org/10.1182/blood-2023-181298
, 2022, 'Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and Sumoylation Blockade in Myelodysplastic Syndromes and Acute Myeloid Leukemia', in Blood, American Society of Hematology, Vol. 140, pp. 220 - 221, http://dx.doi.org/10.1182/blood-2022-165713
, 2021, 'Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC).', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 81, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 10 April 2021 - 21 May 2021
, 2021, 'Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 81, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 10 April 2021 - 21 May 2021
, 2021, 'The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL).', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, Vol. 81, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 10 April 2021 - 21 May 2021
, 2020, 'DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM', in Neuro-Oncology, Oxford University Press (OUP), Vol. 22, pp. iii302 - iii302, http://dx.doi.org/10.1093/neuonc/noaa222.117
, 2020, 'A Novel Engineered Single-Chain Antibody Fragment for Targeting Pediatric Philadelphia Chromosome-like Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, Vol. 136, pp. 36, http://dx.doi.org/10.1182/blood-2020-138421
, 2020, 'Abstract SY09-02: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer in Australia', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. sy09-02-sy09-02, http://dx.doi.org/10.1158/1538-7445.am2020-sy09-02
, 2020, 'Abstract A35: P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. a35 - a35, http://dx.doi.org/10.1158/1538-7445.pedca19-a35
, 2020, 'Abstract A52: Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with high-risk cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. a52 - a52, http://dx.doi.org/10.1158/1538-7445.pedca19-a52
, 2020, 'DIPG-75. PRECISION MEDICINE FOR PAEDIATRIC HIGH-GRADE DIFFUSE MIDLINE GLIOMAS - RESULTS FROM THE ZERO CHILDHOOD CANCER COMPREHENSIVE PRECISION MEDICINE PROGRAM', in Neuro-oncology, Vol. 22, pp. iii302 - iii302
, 2019, 'Zero Childhood Cancer: A Comprehensive Precision Medicine Platform for Children and Adolescents with High-Risk Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S504 - S505, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458005162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 23 - 24, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 61 - 61, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Zero Childhood Cancer (ZERO): A comprehensive precision medicine platform for children with highrisk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 70 - 71, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Abstract 3839: Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts', American Association for Cancer Research (AACR), pp. 3839 - 3839, presented at Experimental and Molecular Therapeutics, http://dx.doi.org/10.1158/1538-7445.sabcs18-3839
, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', American Association for Cancer Research (AACR), pp. 4741 - 4741, presented at Experimental and Molecular Therapeutics, http://dx.doi.org/10.1158/1538-7445.sabcs18-4741
, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 4741 - 4741, http://dx.doi.org/10.1158/1538-7445.am2019-4741
, 2019, 'Abstract 4820: Pediatric preclinical testing consortium evaluation of the CD123 antibody drug conjugate, IMGN632, against xenograft models of pediatric acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 4820 - 4820, http://dx.doi.org/10.1158/1538-7445.am2019-4820
, 2019, 'Abstract 4820: Pediatric preclinical testing consortium evaluation of the CD123 antibody drug conjugate, IMGN632, against xenograft models of pediatric acute lymphoblastic leukemia', American Association for Cancer Research (AACR), pp. 4820 - 4820, presented at Experimental and Molecular Therapeutics, http://dx.doi.org/10.1158/1538-7445.sabcs18-4820
, 2019, 'RESULTS OF THE ZERO CHILDHOOD CANCER INTEGRA-TM PRECISION MEDICINE PLATFORM FOR PAEDIATRIC HIGH-RISK BRAIN TUMOURS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, CA, San Francisco, Vol. 21, pp. 118 - 118, presented at 5th Biennial Conference of the Society-for-Neuro-Oncology on Pediatric Neuro-Oncology Basic and Translational Research, CA, San Francisco, 03 May 2019 - 04 May 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473243700229&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3111
, 2018, 'Abstract LB-137: Integrated genomics: drug screening and personalized xenograft development approach to identify precision treatments for aggressive pediatric brain tumors', in Cancer Research, American Association for Cancer Research (AACR), Vol. 78, pp. lb-137-lb-137, http://dx.doi.org/10.1158/1538-7445.am2018-lb-137
, 2018, 'Abstract LB-138: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 78, pp. lb-138-lb-138, http://dx.doi.org/10.1158/1538-7445.am2018-lb-138
, 2018, 'PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia', in ESMO Open, Elsevier, Vol. 3, pp. a238, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.563
, 2018, 'Zero childhood cancer – Accelerating translation of experimental oncology: Better matching drug to target', in Pathology, Elsevier, Vol. 50, pp. s31, http://dx.doi.org/10.1016/j.pathol.2017.12.072
, 2017, 'REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, SPAIN, Madrid, Vol. 102, pp. 27 - 27, presented at 22nd Congress of the European-Hematology-Association, SPAIN, Madrid, 22 June 2017 - 25 June 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000404127001055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'Pilot study of a comprehensive precision medicine platform for children with high-risk cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, pp. 10539 - 10539, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.10539
, 2017, 'Therapeutic targeting of a9b1 and a4b1 integrins for chemosensitization of drug resistant acute leukaemia', in Experimental Hematology, Elsevier, Vol. 53, pp. s75, http://dx.doi.org/10.1016/j.exphem.2017.06.158
, 2016, 'Comparison of MRD Levels and Gene Expression Patterns in MLL-R Versus Non-MLL Infant ALL', in Blood, American Society of Hematology, Vol. 128, pp. 1740, http://dx.doi.org/10.1182/blood.v128.22.1740.1740
, 2015, 'Efficacy of Focal Adhesion Kinase Inhibition in Combination with Dasatinib in BCR-ABL1 Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, Vol. 126, pp. 3766, http://dx.doi.org/10.1182/blood.v126.23.3766.3766
, 2015, 'Evaluation of Patient-Derived Xenografts for Modeling Outcome of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, Vol. 126, pp. 3759, http://dx.doi.org/10.1182/blood.v126.23.3759.3759
, 2015, 'A REVIEW OF NEW AGENTS TESTED BY THE PEDIATRIC PRECLINICAL TESTING PROGRAM AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS', in PEDIATRIC BLOOD & CANCER, WILEY-BLACKWELL, Vol. 62, pp. S211 - S211, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000361247200258&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2015, 'Abstract 1611: The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting', in Cancer Research, American Association for Cancer Research (AACR), Vol. 75, pp. 1611 - 1611, http://dx.doi.org/10.1158/1538-7445.am2015-1611
, 2015, 'Abstract 3276: Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program', in Cancer Research, American Association for Cancer Research (AACR), Vol. 75, pp. 3276 - 3276, http://dx.doi.org/10.1158/1538-7445.am2015-3276
, 2014, 'Identifying the Factors Modulating the Efficacy of CAR-T Cell Therapy', in Blood, American Society of Hematology, Vol. 124, pp. 5813, http://dx.doi.org/10.1182/blood.v124.21.5813.5813
, 2014, 'Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)', in Blood, American Society of Hematology, Vol. 124, pp. 2322, http://dx.doi.org/10.1182/blood.v124.21.2322.2322
, 2014, 'Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling', in Blood, American Society of Hematology, Vol. 124, pp. 969, http://dx.doi.org/10.1182/blood.v124.21.969.969
, 2014, 'Identifying the factors modulating the efficacy of car-t cell therapy', in Cytotherapy, Elsevier, Vol. 16, pp. s7, http://dx.doi.org/10.1016/j.jcyt.2014.01.015
, 2013, 'Abstract C206: Pediatric Preclinical Testing Program (PPTP) evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide (TMZ).', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), Vol. 12, pp. c206 - c206, http://dx.doi.org/10.1158/1535-7163.targ-13-c206
, 2011, 'Role of Connective Tissue Growth Factor (CTGF) in Survival and Chemosensitivity of Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, Vol. 118, pp. 2593, http://dx.doi.org/10.1182/blood.v118.21.2593.2593